Holds one active US DMF and one valid CEP for irbesartan, filing since 2004. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 23 markets.
Holds one active US DMF and 2 valid CEPs for irbesartan, filing since 2010. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 29 markets.
Holds one active US DMF and 2 valid CEPs for irbesartan, filing since 2006. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 26 markets.
Holds one active US DMF and 2 valid CEPs for irbesartan, filing since 2007. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 18 markets.
Holds one active US DMF and one valid CEP for irbesartan, filing since 2023. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 2 markets.
Holds one active US DMF and one valid CEP for irbesartan, filing since 2021. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 4 markets.
Holds one active US DMF and 2 valid CEPs for irbesartan, filing since 2019. Its 2025 FDA inspection closed as VAI.
Holds one active US DMF and one valid CEP for irbesartan, filing since 2006. Its 2019 FDA inspection closed as NAI, and its GMP is recognised in 1 market.
Holds one active US DMF for irbesartan, filing since 2011. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 20 markets.
Holds 2 valid CEPs for irbesartan, filing since 2024. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 17 markets.
Holds one valid CEP for irbesartan, filing since 2024. Its 2026 FDA inspection closed as VAI, and its GMP is recognised in 13 markets.
Holds one active US DMF for irbesartan, filing since 2012. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 10 markets.
Holds one active US DMF for irbesartan, filing since 1993. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 33 markets.
Holds one active US DMF for irbesartan, filing since 2011. Its 2025 FDA inspection closed as NAI.
Holds one active US DMF for irbesartan, filing since 2007. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 25 markets.
Holds one active US DMF and one valid CEP for irbesartan, filing since 2009. Its 2025 FDA inspection closed as VAI.
Registered with SFDA (Saudi Arabia) for irbesartan. Its 2024 FDA inspection closed as VAI, and its GMP is recognised in 18 markets.
Holds 2 valid CEPs for irbesartan, filing since 2024. Its 2024 FDA inspection closed as VAI.
Holds one active US DMF and one valid CEP for irbesartan, filing since 2025. Its 2022 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
Holds one active US DMF and one valid CEP for irbesartan, filing since 2008. Its 2025 FDA inspection closed as OAI, and its GMP is recognised in 1 market.
The names are listed below. The filings, inspection history and GMP certificates behind each one are available with a free account.
Contract manufacturers make to order rather than holding their own filing for this molecule.
The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Every factor appears on the card it produced. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for free| Year | Median | Exporters |
|---|---|---|
| 2026 YTD | $82.21 | 5 |
| 2025 | $111.01 | 18 |
| 2024 | $131.88 | 16 |
| 2023 | $142.15 | 22 |
US dollars per kilogram, customs export unit values.